AMG 531
Sponsors
Amgen, M.D. Anderson Cancer Center, Kyowa Kirin Co., Ltd.
Conditions
Advanced CancerCancerChemotherapy-Induced ThrombocytopeniaHodgkin's LymphomaIdiopathic Thrombocytopenic PurpuraImmune (Idiopathic) Thrombocytopenic Purpura (ITP)LymphomaMyelodysplastic Syndromes
Phase 1
AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
CompletedNCT00147225
Start: 2005-08-31End: 2013-03-31Updated: 2014-05-08
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
CompletedNCT00283439
Start: 2005-10-31End: 2008-09-30Updated: 2011-06-20
Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma
CompletedNCT00299182
Start: 2006-03-31End: 2012-04-30Updated: 2021-09-21
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
CompletedNCT00515203
Start: 2007-07-31End: 2009-08-31Updated: 2014-07-25
Phase 2
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid
CompletedNCT00418665
Start: 2006-12-31End: 2010-10-31Updated: 2011-01-24
Open Label Extension Study of AMG 531 in Japanese Subjects With ITP
CompletedNCT00440037
Start: 2006-11-30End: 2011-09-30Updated: 2020-01-21
Phase 3
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
CompletedNCT00102336
Start: 2005-04-07End: 2007-04-01Updated: 2022-11-08
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
CompletedNCT00102323
Start: 2005-03-29End: 2007-03-01Updated: 2022-11-07
P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
CompletedNCT00603642
Start: 2007-10-01End: 2009-04-13Updated: 2022-11-08